About this trial
The purpose of this study is to test whether prophylactic application of haemostatic gel will reduce the rate of clinically significant bleeding requiring intervention (such as blood transfusion, admission to hospital, other blood products) following endoscopic resection of advanced duodenal neoplasia compared to standard therapy.
Eligibility criteria
Qualifiers
Single ampullary lesion ≥ 10mm
Resection via hot ampullectomy, injection/Endoscopic mucosal resection of adjacent lateral spreading component Duodenal Lesions
≤ 2 lesions
Lesion ≥15mm
Disqualifiers
Inability to provide informed consent (including people with cognitive impairment);
Pregnant or breastfeeding women;
Allergy to PuraStat®;
"Cold" mucosal endoscopic resection;
Trial design
Treatments tested in this trial
- duodenal mucosectomy
- ampullectomy
Treatment groups
Sponsors and collaborators
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead sponsor
Euraxi Pharma
Collaborator